Regulatory Articles

Regulatory Beat: Pharmaceutical Pricing and Healthcare Access Lead Policy Agenda

Rising healthcare costs and the pressure to expand medical coverage focus public attention o­n medicine outlays.

For full article Click Here

Author(s): 
Jill Wechsler.
Journal: 
BioPharm International, March 2004.

Cohen's Corner: Don't sell out the value of pharmacy

When did retail pharmacy, and, more specifically, the art and professionalism of dispensing a prescription become a commodity? I'm sure every retail pharmacist has a different answer depending o­n how new he or she is to the profession; I know I do. For me, it was back in 1969, when I was just fresh out of school, thinking that pharmacy was the greatest profession in the world. The store I interned in had its fair share of indigent patients who got their prescriptions filled o­n what was then a small federal government program known as Medicaid.


For full article
Click Here

Author(s): 
Harold E. Cohen, R.Ph.
Journal: 
Drug Topics, May 17, 2004 .

Independent Movement of the Regulatory and Catalytic Domains of Myosin Heads

flexibility of the myosin head was measured using phosphorescence anisotropy of selectively labeled parts of the molecule. Phosphorescence anisotropy was measured in soluble S1 and myosin, with and without F-actin, as well as in synthetic myosin filaments. The anisotropy of the former were too low to observe differences in the domain mobilities, including when bound to actin. However, this was not the case in the myosin filament.

For full article Click Here

Author(s): 
Louise J. Brown, Nicholas Klonis, William H. Sawyer, Peter G. Fajer, and Brett D. Hambly.
Journal: 
BiochemistryJune 22, 2001.

PhRMA Perspectives on Drug Substance Regulatory Filing Issues

Tom Cupps,Betsy Fritschel,Wendy Mavroudakis,Michael Mitchell, Dave Ridge, and Jean Wyvratt The PhRMA API Technical Group examines topics concerning active pharmaceutical ingredient development and manufacture and makes recommendations for regulatory guidance.


For full article
Click here



Author(s): 
Tom Cupps,Betsy Fritschel,Wendy Mavroudakis,Michael Mitchell, Dave Ridge, Jean Wyvratt .
Journal: 
The PhRMA API.

Upgrading a Pharmaceutical Laboratory to Part 11 Compliance

FDA's regulation 21 CFR Part 11 o­n Electronic Records and Electronic Signatures provides industry with the requirements that allow electronic records and signatures in computerized systems in place of paper records and handwritten signatures.1

For full article Click Here

Author(s): 
Akos Bartha, Ph.D , Karin Östergren, M.Sc..
Journal: 
BioPharm International, May 2004.

European Regulatory Agencies Resource Locator

Change is in the air for European regulations. Formal legislative proposals might not appear until 2002, but the shape of the changes is beginning to become clear

For full article Click Here

Author(s): 
peterO'Donnell.
Journal: 
Applied Clinical Trials, Dec 1, 2001.

Dissolution testing: An overview and a summary of recent trends and regulatory a

Dissolution testing is critical to measuring the performance of pharmaceutical products in tablet and capsule form. It is a relatively new analytical technique, and equipment modifications and improvements span the decade. This article gives an overview of the apparatuses and procedures used in dissolution testing. It also summarizes the activities of the major organizations and groups that influence dissolution testing standards.

For full-text article
Click Here

Author(s): 
Vivian A. Gray, V. A. Gray .
Journal: 
Consulting, Inc.Tablets& Capsules, October 2003

Part 11 Is Not Going Away: The New Electronic Records Draft Guidance

The rules for electronic records and signatures still remain in effect. The change means that companies must now justify their decisions o­n whether or not to implement specific electronic controls with documented risk assessments and considerations of the record requirements detailed in the corresponding predicate rule.

View Full Article

Author(s): 
Wolfgang Winter, Agilent Technologies GmbH and Ludwig Huber, Agilent Technologies GmbH .
Journal: 
BioPharm International, May 2003.

Anticipating New Regulatory Hurdles

The potential of the biotechnology industry to provide blockbuster products is clearly demonstrated by examples like Enbrel (for the treatment of rheumatoid arthritis in adults and of active polyarticular-course juvenile chronic arthritis), Remicade (for the treatment of rheumatoid arthritis and Crohn's disease), and MabThera (for treatment of stage III-IV follicular lymphoma and CD20 positive diffuse large B-cell non-Hodgkin's lymphoma).

View Full Article

Author(s): 
Emmanuelle M. Voisin.
Journal: 
Applied Clinical Trials, May 1, 2004.

Manufacture of Sterile Active Pharmaceutical Ingredients, guidance, 1999

Active Pharmaceuticals Ingredients Committee of CEFIC.

Syndicate content